Benzinga | May 28, 2021 08:02AM EDT

Chiasma's Mycapssa Associated With Positive Patient-Reported Outcomes In Acromegaly Patients

* Chiasma Inc (NASDAQ:CHMA) has presented patient-reported outcomes (PROs) data from its MPOWERED Phase 3 trial of Mycapssa for acromegaly, a hormonal disorder in which the pituitary gland produces too much growth hormone.

* Data demonstrated that study patients reported significantly improved quality of life and work productivity after transitioning from long-acting injectable somatostatin analogs (iSSAs) to Mycapssa.

* The data were presented at the Annual American Association of Clinical Endocrinology Meeting.

* In the MPOWERED study, 146 patients entered the 6-month run-in phase in which all patients received Mycapssa.

* 92 patients who were responders to Mycapssa at the end of run-in were then randomized into the 9-month randomized controlled treatment phase to receive Mycapssa or iSSAs.

* Among the 92 randomized patients, results showed that several PROs, including quality of life and work productivity, were significantly improved at the end of the run-in phase (reflecting outcomes on Mycapssa) compared to their results at the baseline of run-in (reflecting outcomes on iSSAs).

* The safety profile of Mycapssa in the MPOWERED trial was consistent with the known safety profile of octreotide but without adverse injection site reactions.

* No new or unexpected safety signals were detected during the study.

* Price Action: CHMA shares are up 0.23% at $4.29 during the premarket session on the last check Friday.